Edition:
United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

23.99EUR
11:35am EDT
Change (% chg)

€0.10 (+0.42%)
Prev Close
€23.89
Open
€23.86
Day's High
€24.10
Day's Low
€23.85
Volume
459,900
Avg. Vol
671,470
52-wk High
€28.07
52-wk Low
€21.50

Chart for

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.58
Market Cap(Mil.): €14,776.09
Shares Outstanding(Mil.): 687.55
Dividend: 0.20
Yield (%): 0.85

Financials

  GRLS.MC Industry Sector
P/E (TTM): 23.19 30.29 32.55
EPS (TTM): 1.03 -- --
ROI: 6.81 13.14 12.80
ROE: 18.65 15.07 14.92

Healthcare firm Grifols S.A. wins U.S. antitrust nod to buy Biotest US Corp

WASHINGTON Global healthcare company, Grifols S.A. , which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

Aug 01 2018

Healthcare firm Grifols S.A. wins US antitrust nod to buy Biotest US Corp

WASHINGTON, Aug 1 Global healthcare company, Grifols S.A., which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

Aug 01 2018

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Firday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

May 25 2018

BRIEF-Grifols Expands Its Blood Typing Solutions Portfolio In US With Antisera Reagents

* GRIFOLS EXPANDS ITS BLOOD TYPING SOLUTIONS PORTFOLIO IN THE UNITED STATES WITH ANTISERA REAGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 14 2018

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

May 03 2018

Earnings vs. Estimates